Literature DB >> 1652311

Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.

P Reusser1, S R Riddell, J D Meyers, P D Greenberg.   

Abstract

The high rate of severe cytomegalovirus (CMV) disease after bone marrow transplantation (BMT) is related to the profound immunodeficiency posttransplant. Because cytotoxic T lymphocytes (CTL) have been implicated in resistance to viral infections, we examined the restoration of the CMV-specific CTL response in 20 patients who received bone marrow from HLA-matched, CMV-seropositive donors. Blood specimens were obtained from patients at 1, 2, and 3 months after BMT and from the donors on a single occasion. Peripheral blood mononuclear cells were cocultured with CMV-infected donor-derived fibroblasts for 2 weeks and then tested for cytotoxicity against CMV-infected and uninfected autologous or HLA-mismatched fibroblasts. Cytolytic activity was detected in all 20 donors, with specificity for autologous CMV-infected targets demonstrable in 17 (median CMV-specific lysis at an effector:target ratio of 15:1 was 32%, range 18% to 83%). Specific lysis was mediated by CD8+, class I-restricted T cells, as shown by inhibition with anti-class I monoclonal antibody and by selective depletion of effector cells. By contrast, CMV-specific CTL were detected in only 10 of 20 patients after BMT (median lysis 29% at 3 months post-BMT). None of these 10 patients developed CMV pneumonia, whereas 6 of the 10 patients with an undetectable CMV-specific CTL response after BMT died with CMV pneumonia. These results demonstrate that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease. Approaches to reconstitute CMV immunity in BMT patients by adoptive transfer of CMV-specific CD8+ CTL clones derived from the bone marrow donor are now being pursued.

Entities:  

Mesh:

Year:  1991        PMID: 1652311

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  138 in total

1.  CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS.

Authors:  H Choremi-Papadopoulou; N Panagiotou; E Samouilidou; F Kontopidou; V Viglis; A Antoniadou; J Kosmidis; T Kordossis
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Authors:  G M Gillespie; M R Wills; V Appay; C O'Callaghan; M Murphy; N Smith; P Sissons; S Rowland-Jones; J I Bell; P A Moss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 6.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

7.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 8.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

9.  Successful allogeneic bone marrow transplantation in a patient with acute myelogenous leukemia and cytomegalovirus retinitis.

Authors:  Hiroshi Matsubara; Souichi Adachi; Jun Yano; Noriko Kitamura; Maki Miyazaki; Yasuhiro Mizushima; Hidefumi Hiramatsu; Michihiro Kobayashi; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 10.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.